<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02483793</url>
  </required_header>
  <id_info>
    <org_study_id>15-065</org_study_id>
    <nct_id>NCT02483793</nct_id>
  </id_info>
  <brief_title>Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population</brief_title>
  <official_title>Randomized Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Discomfort in the Pediatric Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenix Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phoenix Children's Hospital</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety tamsulosin in
      reducing stent discomfort in the pediatric population in the peri-operative period. The
      secondary objective is to compare the efficacy of tamsulosin with that of oxybutynin in
      reducing stent discomfort.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of doses of pain in medication used</measure>
    <time_frame>5 days post-op</time_frame>
    <description>After surgery, each child will be prescribed the standard dosage of oxycodone/acetaminophen based on their weight. We will have the patient's family record the number of doses of narcotics used from post-operative day #1 to post-operative day #5 to assess their pain needs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain scale based on the faces pain score</measure>
    <time_frame>5 days post-op</time_frame>
    <description>We will have the family members record the child's pain score in the morning and evening using the faces pain scale and record the score.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Disorder of Urinary Stent</condition>
  <arm_group>
    <arm_group_label>Oxybutynin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be prescribed oxybutynin as well as standard narcotic pain medications. Oxybutynin will be prescribed based off of standard dosing. Patients who are unable to swallow pills will be given oxybutynin elixir (0.5mg/kg/day, divided TID). Patients who are able to swallow pills will be given oxybutynin 5mg either BID or TID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be prescribed tamsulosin and standard narcotic pain medication. Patients will be given tamsulosin 0.4mg at bedtime. This dosage has been used in other studies for children age â‰¥ 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <arm_group_label>Tamsulosin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin</intervention_name>
    <arm_group_label>Oxybutynin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 4-18 years will be enrolled in this study. We will include all patients
             who will have a ureteral stent placement after their procedure.

        Exclusion Criteria:

          -  Patients with developmental delay or unable to verbalize their pain level will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Nguyen, MD</last_name>
    <phone>(602) 933-5200</phone>
    <email>mtn1023@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Chen, MD</last_name>
    <phone>(602) 933-5200</phone>
    <email>catherine.j.chen@gmail.com</email>
  </overall_contact_backup>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2015</study_first_posted>
  <last_update_submitted>June 26, 2015</last_update_submitted>
  <last_update_submitted_qc>June 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

